Navigation Links
NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
Date:4/2/2013

AMES, Iowa, April 2, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer. The Phase 2 clinical study will evaluate indoximod as a new approach to treating cancer by administering this novel IDO pathway inhibitor, designed to counteract a key mechanism by which tumors evade immune-mediated destruction, in combination with a conventional cytotoxin, docetaxel. This Phase 2 clinical study follows the successful Phase 1b dose-escalation study of indoximod in patients with advanced solid tumors in which a favorable safety profile and promising early signs of activity were observed. Indoximod is the most advanced product candidate to enter clinical trials based on NewLink's proprietary IDO pathway inhibitor platform for small-molecule, orally bioavailable cancer immunotherapies.

"There is significant unmet need for new approaches that may offer more effective treatment options for patients with metastatic breast cancer, a leading cause of death in women in the United States," said Hatem Soliman , MD, a medical oncologist specializing in breast cancer in The Center for Women's Oncology at Moffitt Cancer Center and the principal investigator for this study. "Indoximod has demonstrated promising safety, pharmacokinetic and biologic activity in earlier clinical studies and we look forward to increasing our understanding of its potential in metastatic breast cancer with this robust Phase 2 study designed to evaluate the activity of indoximod in combination with a co
'/>"/>

SOURCE NewLink Genetics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Epigenetics: Changing the Way We Think about DNA
2. Research and Markets: Cytogenetics - Technologies, Markets and Companies - 2013
3. Plunketts Biotech & Genetics Industry Almanac 2013: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies
4. Plunketts Biotech & Genetics Industry Trends & Statistics 2013: A Summary Version of Plunketts Biotech & Genetics Industry Almanac 2013
5. GeneTex Launches New Antibody Against Phosphorylated Histone H3 for Epigenetics Research
6. The American College of Obstetricians and Gynecologists Committee on Genetics and the Society for Maternal-Fetal Medicine Publications Committee Recommend Noninvasive Prenatal Testing for Fetal Aneuploidy
7. Response Genetics, Inc. to Offer ROS1 Testing for Lung Cancer
8. Epigenetics Holds Key to Healthier Future
9. Response Genetics, Inc. Announces Second Quarter Financial Results
10. Genetics Policy Institute (GPI) Collaborates on Second Midwest Conference on Stem Cell Biology and Therapy, Oct. 5-7 at Oakland University
11. Applied Genetics Initiates Commercial Operation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
(Date:1/15/2014)... 15, 2014 The Microcompetition with Foreign DNA ... One of these latent viruses is the Epstein Barr Virus ... Rheumatoid arthritis (RA) is a chronic inflammatory disease that destroys ... found that RA patients have high concentrations of EBV DNA ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... Therapeutics, Inc.,(Nasdaq: TPTX ) today announced that ... in certain royalty amounts that may become payable to ... and tezampanel,should either or both gain regulatory approval. Specifically, ... points and the middle tier,royalty rate will be reduced ...
... Pa., Nov. 25 Tengion Inc., a clinical stage regenerative medicine ... that Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion, ... Tuesday, December 2, 2008 at 9:50 a.m. EST at The Palace ... , About Tengion , ...
... 25 /PRNewswire-Asia/ -- ScinoPharm, an active,pharmaceutical ingredient (API) ... 7,435,818 entitled "Novel Crystal Forms of Irinotecan,Hydrochloride." The ... hydrochloride and processes for their preparation as well ... of treating,metastatic carcinoma of the colon or rectum ...
Cached Biology Technology:TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel 2ScinoPharm Granted US Patent for Novel Crystal Forms 2
(Date:4/20/2014)... Mothers give a newborn baby a gift of ... system. But antibiotics, used to fend off infection, ... leaving already-vulnerable premature babies more susceptible to dangerous ... neonatology researchers at The Children,s Hospital of Philadelphia ... revealing how gut microbes play a crucial role ...
(Date:4/18/2014)... decades, scientists have used techniques like X-ray crystallography and ... into the atomic structure of molecules, but such efforts ... demand large quantities of a specific molecule and often ... making it all but impossible to peer into the ... those problems may soon be a thing of the ...
(Date:4/18/2014)... Durham, NC Seeds that sprout as soon as they,re ... plants need to be more careful. In the wild, a ... rainy day would risk disaster. More than just an insurance ... out that seed dormancy has long-term advantages too: Plants ... give rise to more species, finds in a team of ...
Breaking Biology News(10 mins):Study of gut microbes, antibiotics: Clues to improving immunity in premature infants 2MRI, on a molecular scale 2MRI, on a molecular scale 3Plants with dormant seeds give rise to more species 2
... antibiotic used to boost organ survival in transplant ... the heart against tissue damage following acute heart ... Journal of Molecular and Cellular Cardiology, the official ... researchers demonstrated for the first time that pretreatment ...
... to change their spots, but corals can change their skeletons, ... composition of the seawater around them. , That's the startling ... in the July issue of the journal Geology. , ... the first known case of an animal altering the composition ...
... University in St. Louis and their collaborators from Taiwan ... varieties and have determined that the crop was domesticated ... Jason Londo, Washington University in Arts & Sciences biology ... Washington University Spencer T. Olin Professor of Biology in ...
Cached Biology News:New study shows antibiotic may protect the heart 2Corals switch skeleton material as seawater changes 2Corals switch skeleton material as seawater changes 3Biologists find regions of rice domestication 2
Mouse Wnt-9b Affinity Purified Polyclonal Ab Keywords: Wnt 9b Protein Family: Cancer Stem Cell Markers, Wnt Ligands...
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
One-step, microplate or cuvet, colorimetric, linear detection range 6 mg/dL to 100mg/dL. Procedure: 15 min....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
Biology Products: